Evidence map›Paper›PMID 36636451›Full record

ReviewJACC. CardioOncology2022

Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:

Sean Tan, Daphne Day, Stephen J Nicholls, Eva Segelov

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Prospective serial cardiovascular magnetic resonance imaging of immune checkpoint inhibitor myocarditis correlates with cardiovascular outcomes.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2026
    Article
  20. Review

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sean TanVictorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
Daphne DaySchool of Clinical Sciences, Monash Health, Monash University, Melbourne, Victoria, Australia.
Stephen J NichollsVictorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
Eva SegelovSchool of Clinical Sciences, Monash Health, Monash University, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that have significantly improved the prognosis of various cancers, both in (neo)adjuvant and metastatic settings. Unlike other conventional therapies, ICIs elicit antitumor effects by enhancing host immune systems to eliminate cancer cells. There are 3 approved ICI classes by the U.S. Food and Drug Administration: inhibitors targeting cytotoxic T lymphocyte associated antigen 4, programmed death 1/programmed death-ligand 1, and lymphocyte-activation gene 3, with many more in development. ICIs are commonly associated with distinct toxicities, known as immune-related adverse events, which can arise during treatment or less frequently be of late onset, usually relating to excessive activation of the immune system. Acute cardiovascular immune-related adverse events such as myocarditis are rare; however, data suggesting chronic cardiovascular sequelae are emerging. This review presents the current landscape of ICIs in oncology, with a focus on important aspects relevant to cardiology.

Indexed as

biomarkerscardio-oncologycardiotoxicityCTLA-4, cytotoxic T lymphocyte associated antigen 4ICI, immune checkpoint inhibitorsimmune checkpoint inhibitorsimmune related adverse eventsimmunotherapyirAE, immune-related adverse eventLAG-3, lymphocyte-activation gene 3medical oncologyMSI, microsatellite instabilityPD-L1, programmed death-ligand 1TMB, tumor mutational burdenTME, tumor microenvironment

Identifiers

PMID36636451
PMCPMC9830229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.